Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EDS01 plus chemotherapy in advanced head and neck cancer
CTR20140842Phase 2Active
- Sponsor
- Chengdu Endos Biotechnology
- Start
- May 2015
- Modality
- Oncolytic Viruses → Oncolytic Therapeutics, Gene Therapies, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of Recombinant human endostatin adenovirus in head and neck cancer (HNC), head and neck squamous cell carcinoma (HNSCC), nasopharyngeal carcinoma (NPC), sponsored by Chengdu Endos Biotechnology. Started May 2015; status: active.
02
Drugs
Recombinant human endostatin adenovirus
03
Conditions
head and neck cancer (HNC)head and neck squamous cell carcinoma (HNSCC)nasopharyngeal carcinoma (NPC)
Beyond the preview
Go deeper on CTR20140842.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20140842.